CN111527077B - 通过添加o,o′-二取代酒石酸对映异构体进行外消旋烟碱的对映异构体分离 - Google Patents
通过添加o,o′-二取代酒石酸对映异构体进行外消旋烟碱的对映异构体分离 Download PDFInfo
- Publication number
- CN111527077B CN111527077B CN201880083325.7A CN201880083325A CN111527077B CN 111527077 B CN111527077 B CN 111527077B CN 201880083325 A CN201880083325 A CN 201880083325A CN 111527077 B CN111527077 B CN 111527077B
- Authority
- CN
- China
- Prior art keywords
- tartaric acid
- nicotine
- enantiomer
- formula
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 127
- 150000003892 tartrate salts Chemical class 0.000 title claims abstract description 49
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Chemical compound CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract description 37
- 238000000926 separation method Methods 0.000 title abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 37
- 230000008569 process Effects 0.000 claims abstract description 24
- YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 150000001875 compounds Chemical class 0.000 claims description 32
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 23
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 5
- YONLFQNRGZXBBF-ZIAGYGMSSA-L (2r,3r)-2,3-dibenzoyloxybutanedioate Chemical compound O([C@@H](C(=O)[O-])[C@@H](OC(=O)C=1C=CC=CC=1)C([O-])=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-L 0.000 claims description 4
- MVODTGURFNTEKX-UHFFFAOYSA-N 2-bromo-n-(2-bromoethyl)-n-(thiophen-2-ylmethyl)ethanamine;hydrobromide Chemical compound Br.BrCCN(CCBr)CC1=CC=CS1 MVODTGURFNTEKX-UHFFFAOYSA-N 0.000 claims description 4
- ZWJMXJUZYGTMSZ-UHFFFAOYSA-N bis(2-methylbenzoyl) 2,3-dihydroxybutanedioate Chemical compound CC1=CC=CC=C1C(=O)OC(=O)C(O)C(O)C(=O)OC(=O)C1=CC=CC=C1C ZWJMXJUZYGTMSZ-UHFFFAOYSA-N 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 51
- 229960002715 nicotine Drugs 0.000 abstract description 47
- 229930182840 (S)-nicotine Natural products 0.000 abstract description 22
- SNICXCGAKADSCV-SNVBAGLBSA-N (+)-nicotine Chemical compound CN1CCC[C@@H]1C1=CC=CN=C1 SNICXCGAKADSCV-SNVBAGLBSA-N 0.000 abstract description 14
- 229930182841 (R)-nicotine Natural products 0.000 abstract description 11
- 239000003795 chemical substances by application Substances 0.000 description 46
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- XBLVHTDFJBKJLG-UHFFFAOYSA-N Ethyl nicotinate Chemical compound CCOC(=O)C1=CC=CN=C1 XBLVHTDFJBKJLG-UHFFFAOYSA-N 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 9
- 229940064982 ethylnicotinate Drugs 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- DPNGWXJMIILTBS-UHFFFAOYSA-N myosmine Chemical compound C1CCN=C1C1=CC=CN=C1 DPNGWXJMIILTBS-UHFFFAOYSA-N 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 229960001367 tartaric acid Drugs 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- -1 transdermal patches Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000002355 alkine group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960001270 d- tartaric acid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- NTOIKDYVJIWVSU-WOJBJXKFSA-N (2r,3r)-2,3-dihydroxy-2,3-bis(4-methylbenzoyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)[C@@](O)(C(O)=O)[C@](O)(C(O)=O)C(=O)C1=CC=C(C)C=C1 NTOIKDYVJIWVSU-WOJBJXKFSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HOTGVXAUSA-N (2s,3s)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@H](C(O)=O)[C@@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HOTGVXAUSA-N 0.000 description 1
- IRJNJBIOUYJBHG-PPHPATTJSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CN1CCC[C@H]1C1=CC=CN=C1 IRJNJBIOUYJBHG-PPHPATTJSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- CJIGBKOFGVXBDN-LDVZRWNISA-N C(C1=CC=CC=C1)(=O)[C@@]([C@@](C(=O)O)(O)C(C1=CC=CC=C1)=O)(O)C(=O)O.N1=CC=CC(=C1)[C@@H]1N(C)CCC1 Chemical compound C(C1=CC=CC=C1)(=O)[C@@]([C@@](C(=O)O)(O)C(C1=CC=CC=C1)=O)(O)C(=O)O.N1=CC=CC(=C1)[C@@H]1N(C)CCC1 CJIGBKOFGVXBDN-LDVZRWNISA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010043903 Tobacco abuse Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003571 electronic cigarette Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- DGEYTDCFMQMLTH-UHFFFAOYSA-N methanol;propan-2-ol Chemical compound OC.CC(C)O DGEYTDCFMQMLTH-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960001238 methylnicotinate Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17210181.8 | 2017-12-22 | ||
| EP17210181 | 2017-12-22 | ||
| PCT/EP2018/085444 WO2019121649A1 (en) | 2017-12-22 | 2018-12-18 | Enantiomeric separation of racemic nicotine by addition of an o,o'-disubstituted tartaric acid enantiomer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111527077A CN111527077A (zh) | 2020-08-11 |
| CN111527077B true CN111527077B (zh) | 2023-03-10 |
Family
ID=60782088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880083325.7A Active CN111527077B (zh) | 2017-12-22 | 2018-12-18 | 通过添加o,o′-二取代酒石酸对映异构体进行外消旋烟碱的对映异构体分离 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US11279685B2 (es) |
| EP (1) | EP3710437B1 (es) |
| JP (1) | JP7030208B2 (es) |
| KR (1) | KR20200103730A (es) |
| CN (1) | CN111527077B (es) |
| AU (1) | AU2018391657B2 (es) |
| BR (1) | BR112020012458A2 (es) |
| CA (1) | CA3085208C (es) |
| CL (1) | CL2020001656A1 (es) |
| DK (1) | DK3710437T3 (es) |
| ES (1) | ES2940319T3 (es) |
| FI (1) | FI3710437T3 (es) |
| HR (1) | HRP20230119T1 (es) |
| HU (1) | HUE061702T2 (es) |
| IL (1) | IL275585B2 (es) |
| LT (1) | LT3710437T (es) |
| MY (1) | MY193072A (es) |
| NZ (1) | NZ765535A (es) |
| PE (1) | PE20211392A1 (es) |
| PL (1) | PL3710437T3 (es) |
| PT (1) | PT3710437T (es) |
| RS (1) | RS64017B1 (es) |
| RU (1) | RU2753492C1 (es) |
| SG (1) | SG11202005641XA (es) |
| SI (1) | SI3710437T1 (es) |
| WO (1) | WO2019121649A1 (es) |
| ZA (1) | ZA202003683B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2898315T3 (es) | 2017-12-22 | 2022-03-07 | Siegfried Ag | Preparación de nicotina racémica mediante reacción de nicotinato de etilo con n-vinilpirrolidona en presencia de una base de alcoholato y etapas de proceso posteriores |
| LU101511B1 (en) * | 2019-12-02 | 2021-06-04 | Herrera Arturo Solis | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a parenteral administration and a process for the preparation of an injectable substance |
| CN111187250B (zh) * | 2020-01-08 | 2023-04-07 | 深圳黑尔格科技有限公司 | 一种拆分式制备光学活性尼古丁的方法 |
| CN114644614B (zh) * | 2021-04-21 | 2023-03-28 | 黄冈中有生物科技有限公司 | 一种左旋烟碱的制备方法 |
| CN115260088A (zh) * | 2021-04-30 | 2022-11-01 | 武汉中有药业有限公司 | 烟碱及其中间体的制备方法 |
| CN113416180A (zh) * | 2021-08-09 | 2021-09-21 | 东莞市鸿馥生物科技有限公司 | 一种(s)-1-甲基-2-(3-吡啶基)吡咯烷的拆分方法 |
| CN114249711A (zh) * | 2022-03-02 | 2022-03-29 | 北京邦克凯姆医药科技有限公司 | 一种拆分制备尼古丁的方法 |
| CN114671852A (zh) * | 2022-04-24 | 2022-06-28 | 仙居两山生物科技有限公司 | 一种高纯度左旋烟碱医药中间体的制备方法 |
| CN115093394A (zh) * | 2022-07-20 | 2022-09-23 | 北京世桥生物制药有限公司 | S-(-)-尼古丁(-)-二苯甲酰-l-酒石酸盐晶型、制备方法及应用 |
| CN115286615A (zh) * | 2022-09-01 | 2022-11-04 | 深圳市真味生物科技有限公司 | 一种消旋尼古丁的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2484673A2 (en) * | 2011-02-02 | 2012-08-08 | Divi's Laboratories Limited | A process for the resolution of (R,S)-nicotine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003342259A (ja) | 2001-12-21 | 2003-12-03 | Toray Ind Inc | 光学活性シスピペリジン誘導体の製造法 |
| JP2006335639A (ja) | 2003-01-23 | 2006-12-14 | Nagase & Co Ltd | 光学活性なフルルビプロフェンの製造方法 |
| CN102617547B (zh) | 2011-01-27 | 2016-02-10 | 上海特化医药科技有限公司 | 一种制备消旋尼古丁的方法 |
| US8367837B2 (en) | 2011-02-14 | 2013-02-05 | Divi's Laboratories, Ltd. | Process for the preparation of (R,S)-nicotine |
| EP3209653B1 (en) | 2014-10-22 | 2021-06-09 | Next Generation Labs, LLC | Process for the preparation of (r,s)-nicotine |
| US9809567B2 (en) * | 2014-12-09 | 2017-11-07 | Njoy, Llc | Synthesis and resolution of nicotine |
| CA3048820A1 (en) | 2015-12-30 | 2017-07-06 | Next Generation Labs, LLC | Nicotine replacement therapy products comprising synthetic nicotine |
| US10421739B2 (en) | 2016-01-08 | 2019-09-24 | Council Of Scientific & Industrial Research | Process for the preparation of nicotine |
| ES2898315T3 (es) | 2017-12-22 | 2022-03-07 | Siegfried Ag | Preparación de nicotina racémica mediante reacción de nicotinato de etilo con n-vinilpirrolidona en presencia de una base de alcoholato y etapas de proceso posteriores |
-
2018
- 2018-12-18 JP JP2020554570A patent/JP7030208B2/ja active Active
- 2018-12-18 AU AU2018391657A patent/AU2018391657B2/en not_active Ceased
- 2018-12-18 SG SG11202005641XA patent/SG11202005641XA/en unknown
- 2018-12-18 IL IL275585A patent/IL275585B2/en unknown
- 2018-12-18 FI FIEP18816112.9T patent/FI3710437T3/fi active
- 2018-12-18 PT PT188161129T patent/PT3710437T/pt unknown
- 2018-12-18 BR BR112020012458-3A patent/BR112020012458A2/pt active Search and Examination
- 2018-12-18 CN CN201880083325.7A patent/CN111527077B/zh active Active
- 2018-12-18 PL PL18816112.9T patent/PL3710437T3/pl unknown
- 2018-12-18 PE PE2020000799A patent/PE20211392A1/es unknown
- 2018-12-18 HU HUE18816112A patent/HUE061702T2/hu unknown
- 2018-12-18 MY MYPI2020003160A patent/MY193072A/en unknown
- 2018-12-18 KR KR1020207020580A patent/KR20200103730A/ko not_active Application Discontinuation
- 2018-12-18 RS RS20230075A patent/RS64017B1/sr unknown
- 2018-12-18 HR HRP20230119TT patent/HRP20230119T1/hr unknown
- 2018-12-18 NZ NZ765535A patent/NZ765535A/en unknown
- 2018-12-18 LT LTEPPCT/EP2018/085444T patent/LT3710437T/lt unknown
- 2018-12-18 DK DK18816112.9T patent/DK3710437T3/da active
- 2018-12-18 US US16/956,964 patent/US11279685B2/en active Active
- 2018-12-18 RU RU2020120637A patent/RU2753492C1/ru active
- 2018-12-18 EP EP18816112.9A patent/EP3710437B1/en active Active
- 2018-12-18 WO PCT/EP2018/085444 patent/WO2019121649A1/en unknown
- 2018-12-18 ES ES18816112T patent/ES2940319T3/es active Active
- 2018-12-18 SI SI201830846T patent/SI3710437T1/sl unknown
- 2018-12-18 CA CA3085208A patent/CA3085208C/en active Active
-
2020
- 2020-06-18 ZA ZA2020/03683A patent/ZA202003683B/en unknown
- 2020-06-18 CL CL2020001656A patent/CL2020001656A1/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2484673A2 (en) * | 2011-02-02 | 2012-08-08 | Divi's Laboratories Limited | A process for the resolution of (R,S)-nicotine |
Non-Patent Citations (1)
| Title |
|---|
| A CONVENIENT METHOD FOR THE PREPARATION OF RACEMIC NICOTINE;Edward R. Bowman,et al.;《Synthetic Communications》;19821231;第12卷(第11期);871-879 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111527077B (zh) | 通过添加o,o′-二取代酒石酸对映异构体进行外消旋烟碱的对映异构体分离 | |
| AU2018391652B2 (en) | Preparation of racemic nicotine by reaction of ethyl nicotinate with N-vinylpyrrolidone in the presence of an alcoholate base and subsequent process steps | |
| EP2484673B1 (en) | A process for the resolution of (R,S)-nicotine | |
| AU695479B2 (en) | Racemisation and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof | |
| EP3474847B1 (en) | Processes for the preparation of eluxadoline | |
| JP2000504684A (ja) | 第４級キラル中心のラセミ化 | |
| KR101748469B1 (ko) | 신규한 니트로기를 포함하는 키랄 테트라히드로퀴놀린 및 키랄 디히드로퀴놀린유도체와 이의 제조방법 | |
| JPH10507173A (ja) | レボブピバカインとその類似体のｌ−リシンからの製造法 | |
| JP2003523997A (ja) | ４−置換−１ｈ−ピロール−３−カルボン酸エステルの新規な製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |